Latest news with #IndiaGlycols
&w=3840&q=100)
Business Standard
26-06-2025
- Business
- Business Standard
This smallcap stock zooms 105% from April low, hits new high; here's why
India Glycols share price Share price of India Glycols hit a new high of ₹2,057, gaining 2 per cent on the BSE in Thursday's intra-day trade. The stock price of the breweries & distilleries company has more-than-doubled or zoomed 105 per cent from its three-month low of ₹1,005 touched on April 7, 2025. In the past one week, India Glycols has appreciated by 14 per cent, as compared to a 2.4 per cent rise in the BSE Sensex. What's driving stock price of India Glycols The board of directors of India Glycols at its meeting held on May 30, 2025 approved the sub-division/split of the 1 equity share having face value of ₹10 each, into 2 equity shares, having face value of ₹5 each. India Glycols said the rationale behind the split is to enhance the liquidity of company's equity shares in the capital market and to encourage wider participation of investors by making equity shares of the company more affordable. Meanwhile, for the March 2025 quarter (Q4FY25), India Glycols reported strong operational performance with earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 35.1 per cent to ₹148 crore from ₹109 crore in Q4FY24. Margins reported a healthy improvement of 532 bps to 17.1 per cent from 11.7 per cent in a year ago quarter. JV reported a strong performance for the full year, with Net Revenue grew by 13 per cent and EBITDA up 70 per cent as compared to FY24, primarily supported by reduced Ethylene Oxide (EO) price gap and product-mix improvement. The company saw strong growth in Country Liquor (CL) and Indian Made Foreign Liquor (IMFL), focusing on premiumisation and penetration into newer markets, supported by partnership with Amrut. Meanwhile, the company said it has been allocated quantities through tender(s) participation for supply of 180.6 million liters of Ethanol with an estimated value aggregating to ₹1,264 crore under Ethanol Blended Petrol Programme (EBPP) for Ethanol Supply Year 1-November-2024 till 31-October-2025. In another development, India Glycols has received the Establishment Inspection Report (EIR) with no observation from US Food and Drug Administration (USFDA) on April 25, 2025 for the company's nutraceutical products and dietary supplements ingredients at Dehradun Plant. The company said the receipt of EIR underscores its commitment to adhering to global quality standards and paves the way for access to the premium the US market, along with other highly regulated global markets. About India Glycols India Glycols is one of the leading manufacturers of Bio-based Specialties & Performance Chemicals (BSPC), Biofuel, Potable Spirits (PS) and Ennature Biopharma (EB). It is the first company in the world to produce Ethylene Oxide (EO) / Mono Ethylene Glycol (MEG) from renewable Agro routes based on molasses since 1989. The company has a diversified portfolio with exposure in Bio-based Specialties, Bio-Polymers, Plant based APIs & Nutraceuticals, Potable Spirits, Gases, Biofuels, and others. The company has a global presence and partners in various countries, with a rich legacy of over three decades in innovation and sustainability.
Yahoo
22-05-2025
- Business
- Yahoo
India Glycols Ltd (BOM:500201) Q4 2025 Earnings Call Highlights: Strong Biofuels Growth Amidst ...
Release Date: May 21, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. India Glycols Ltd (BOM:500201) reported a strong growth in biofuels, with a 48% increase in revenue to 273 crores. The company achieved a significant improvement in EBITDA margin, rising to 17.1% from 11.7% year-on-year. The portable spirit segment saw a notable increase in margins from 16.2% to 27%, indicating strong performance. The joint venture showed a remarkable improvement, with net profit share increasing nearly threefold. India Glycols Ltd (BOM:500201) has successfully expanded its product portfolio in the premium liquor segment through a partnership with Amruth, enhancing its market presence. The net revenue for Q4 2025 saw a marginal decline compared to the previous year, indicating some challenges in maintaining top-line growth. The bio-based specialty chemicals segment experienced a softer quarter with a 17.6% decline in net revenue. The nutraceutical and biopharma segment faced significant pricing pressure due to increased competition and softer international demand. The chemical business reported stagnant growth, with some core segments underperforming. Despite overall growth, the company faces challenges in maintaining profitability in the joint venture due to fluctuating crude prices and associated costs. Warning! GuruFocus has detected 9 Warning Signs with BOM:500201. Q: Given the market is well supplied, is the margin profile for the In Nature Pharma segment expected to be lower than historically? A: (CEO) The market and organization are in transition. We are moving up the value chain with efforts like receiving an establishment inspection report with no observations from the FDA. We are focusing on branded products and demonstrating differentiation in product performance and quality standards. While challenges exist, we have a clear plan to move into higher value spaces, and the business fundamentals remain strong. Q: With crude prices sliding back, how do you foresee the joint venture's performance in the future? A: (CEO) The difference between IPO price and market price has decreased, and we don't expect it to return to previous high levels. We've taken actions to mitigate risks, such as investing in grain-based capacity and diversifying products. The joint venture is more established now, focusing on indigenization and improved product mix, which should help manage pressures. Q: Is the high EBIT margin in the spirits division sustainable in the coming years? A: (CEO) Structurally, we don't see anything that would drastically reduce margins. While there are occasional variations in costs, we are focusing on premiumization and moving up the value chain. There are no immediate red flags suggesting a significant margin decline. Q: What is the return on capital for the spirits business? A: (CFO) The return on capital for the spirits business is around 17 to 18%. Q: How will the debt be allocated between the chemical and liquor divisions post-merger? A: (CFO) Out of the total long-term debt of about 1,200 crores, 500 crores will go to the chemical division and 700 crores to the liquor division. The repayment schedule includes about 150 to 160 crores annually for the liquor division and about 90 crores for the chemical division. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Standard
17-05-2025
- Business
- Business Standard
India Glycols consolidated net profit rises 51.67% in the March 2025 quarter
Sales decline 6.79% to Rs 863.22 crore Net profit of India Glycols rose 51.67% to Rs 64.02 crore in the quarter ended March 2025 as against Rs 42.21 crore during the previous quarter ended March 2024. Sales declined 6.79% to Rs 863.22 crore in the quarter ended March 2025 as against Rs 926.14 crore during the previous quarter ended March 2024. For the full year,net profit rose 33.49% to Rs 230.92 crore in the year ended March 2025 as against Rs 172.99 crore during the previous year ended March 2024. Sales rose 14.40% to Rs 3768.26 crore in the year ended March 2025 as against Rs 3293.97 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 863.22926.14 -7 3768.263293.97 14 OPM % 16.9111.29 - 13.5612.22 - PBDT 114.3881.64 40 407.52324.08 26 PBT 81.7955.60 47 292.32223.31 31 NP 64.0242.21 52 230.92172.99 33
Business Standard
17-05-2025
- Business
- Business Standard
India Glycols standalone net profit rises 33.41% in the March 2025 quarter
Sales decline 6.61% to Rs 862.57 crore Net profit of India Glycols rose 33.41% to Rs 50.35 crore in the quarter ended March 2025 as against Rs 37.74 crore during the previous quarter ended March 2024. Sales declined 6.61% to Rs 862.57 crore in the quarter ended March 2025 as against Rs 923.63 crore during the previous quarter ended March 2024. For the full year,net profit rose 18.88% to Rs 180.38 crore in the year ended March 2025 as against Rs 151.73 crore during the previous year ended March 2024. Sales rose 14.46% to Rs 3767.13 crore in the year ended March 2025 as against Rs 3291.20 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 862.57923.63 -7 3767.133291.20 14 OPM % 16.6511.38 - 13.4512.09 - PBDT 100.7177.16 31 356.97302.81 18 PBT 68.1251.13 33 241.78202.05 20 NP 50.3537.74 33 180.38151.73 19
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
India Glycols hits new high, stock zooms 63% from April low; here's why
Share price of India Glycols hit a new high of ₹1,639.80 on the BSE in Tuesday's intra-day trade and rallied 17% in past two trading days on healthy outlook. SI Reporter Mumbai India Glycols share price today: Share price of India Glycols hit a new high of ₹1,639.80, as it rallied 6 per cent on the BSE in Tuesday's intra-day trade in an otherwise weak market, and extended its previous day's gain on a healthy outlook. In the past two trading days, the stock price of the breweries & distilleries company has surged 17 per cent. It has bounced back 63 per cent from its previous month low of ₹1,005 touched on April 7, 2025. At 10:02 am, India Glycols was trading 5 per cent higher at ₹1,627.05, as compared to the 1.08 per cent rise in the BSE Sensex. Q4 results date, dividend announcement The board of directors of India Glycols is scheduled to meet on Friday, May 16, 2025, to consider and approve the audited financial results of the company for the quarter and financial year ended 31 March, 2025, and recommendation of dividend, if any, for the financial year ended 31 March, 2025. Q3 financial performance In Q3Y25 (October to December 2024), the consolidated revenue from operations increased to ₹2,424 crore, growing 14 per cent year-on-year (YoY). Profit after tax grew 32.5 per cent YoY to ₹71.42 crore from ₹ 53.89 crore in Q4FY24. The company reported healthy margin improvement by 145 bps in earnings before interest, taxes, depreciation and amortisation (Ebitda) margin at 13.2 per cent. Improvement is largely driven by significant scaling up of its recently established distillery facilities which is being used to supply ethanol to oil marketing companies (OMCs) in India. Revenue pressure persists in the Bio-based Specialities and Performance Chemicals Segment (BSPC) segment, where revenue from glycol-based products witnessed pressure from share of decline in substitute product prices, lower demand in Chinese and South-East Asian markets, and the management's decision to restrict supply to domestic markets due to subdued pricing. ALSO READ | Receives EIR from USFDA for Dehradun facility India Glycols has received the Establishment Inspection Report (EIR) with no observation from the US Food and Drug Administration (US FDA) on April 25, 2025, for the Company's nutraceutical products and dietary supplements ingredients at Dehradun Plant. The company said the receipt of EIR underscores its commitment to adhering to global quality standards and paves the way for access to the premium US market, along with other highly regulated global markets. Scheme of arrangement The company in February 2025 has announced composite scheme of arrangement where the holding company, Kashipur Holdings Limited (KHL) is being amalgamated with India Glycols while the bio-pharma undertaking and spirits and biofuel undertaking are being demerged in separate entities, Ennature Bio Pharma Limited (EBL) and IGL Spirits Limited (ISL). The Board of directors' approval has been received. The scheme of arrangement is subject to the requisite approvals and sanction of the jurisdictional bench of National Company Law Tribunal (NCLT). If the current scheme of arrangement is approved, India Glycols will house glycols and new specialities units, hence effectively being a pure chemical manufacturer. CARE Ratings' view on India Glycols Ratings currently continue to take comfort from the company's diversified revenue streams, which mitigate volatility impact in one segment and healthy market position in bio-based glycols, potable spirit (PS), and nutraceutical segment, leading to a large scale of operations. The company has also significantly scaled up its biofuel business over the recent couple of fiscals as well. These businesses are expected to be housed in separate entities in case the scheme is executed. ALSO READ | About India Glycols India Glycols manufactures green technology-based bulk, specialty, and performance chemicals and natural gums, spirits, industrial gases, sugar, and nutraceuticals. It operates under three broad segments: Bio-based specialities and Performance Chemicals (BSPC), Biofuels, PS, and EB. These segments contributed 49 per cent, 16 per cent, 29 per cent and 6 per cent, respectively, to the company's net revenue in FY24.
